[
  {
    "ts": null,
    "headline": "Why 2026 Could Be the Breakout Year for Dividend Growth Investors",
    "summary": "Dividend growth investing has always had an appeal to people who are looking to boost their income, find stability in another unstable market, and build long-term wealth. However, 2026 is shaping up to be something of a turning point as a breakout year for this growing investment philosophy. Between market conditions, earnings trends, and a ... Why 2026 Could Be the Breakout Year for Dividend Growth Investors",
    "url": "https://finnhub.io/api/news?id=8d384204fcda3e55de3c50c73e06194eb6273ed85f604c1c632fe0e9317eb245",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765221037,
      "headline": "Why 2026 Could Be the Breakout Year for Dividend Growth Investors",
      "id": 137737571,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Dividend growth investing has always had an appeal to people who are looking to boost their income, find stability in another unstable market, and build long-term wealth. However, 2026 is shaping up to be something of a turning point as a breakout year for this growing investment philosophy. Between market conditions, earnings trends, and a ... Why 2026 Could Be the Breakout Year for Dividend Growth Investors",
      "url": "https://finnhub.io/api/news?id=8d384204fcda3e55de3c50c73e06194eb6273ed85f604c1c632fe0e9317eb245"
    }
  },
  {
    "ts": null,
    "headline": "2 Dividend Stocks That Jim Cramer Wants Every Retiree to Own",
    "summary": "Retirees and older individuals are among the biggest demographics who tune into Jim Cramer’s Mad Money show. You may disagree with Cramer’s investing methodology and critique his failures, but it’s undeniable that his opinions have sway. And when it comes to long-term dividend investing, those opinions have held up quite well. Cramer’s opinionated takes often ... 2 Dividend Stocks That Jim Cramer Wants Every Retiree to Own",
    "url": "https://finnhub.io/api/news?id=845d141db46ed0cfb238c531637b731d3f0c02f65e872c70f394d5b31503354f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765221025,
      "headline": "2 Dividend Stocks That Jim Cramer Wants Every Retiree to Own",
      "id": 137737732,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Retirees and older individuals are among the biggest demographics who tune into Jim Cramer’s Mad Money show. You may disagree with Cramer’s investing methodology and critique his failures, but it’s undeniable that his opinions have sway. And when it comes to long-term dividend investing, those opinions have held up quite well. Cramer’s opinionated takes often ... 2 Dividend Stocks That Jim Cramer Wants Every Retiree to Own",
      "url": "https://finnhub.io/api/news?id=845d141db46ed0cfb238c531637b731d3f0c02f65e872c70f394d5b31503354f"
    }
  },
  {
    "ts": null,
    "headline": "WTV: Shareholder Yield ETF Outperforming Its Peers",
    "summary": "The WisdomTree U.S. Value Fund ETF excels with high yield, low fees, and top returns. Here's what investors need to know.",
    "url": "https://finnhub.io/api/news?id=7584c324268517f728eb626ab75e9e8b637422f1dfd71e22b718a64b2750bfa0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765219556,
      "headline": "WTV: Shareholder Yield ETF Outperforming Its Peers",
      "id": 137735132,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1478479389/image_1478479389.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "The WisdomTree U.S. Value Fund ETF excels with high yield, low fees, and top returns. Here's what investors need to know.",
      "url": "https://finnhub.io/api/news?id=7584c324268517f728eb626ab75e9e8b637422f1dfd71e22b718a64b2750bfa0"
    }
  },
  {
    "ts": null,
    "headline": "Can J&J Offset Stelara LOE, MedTech China and Legal Headwinds in 2026?",
    "summary": "J&J faces Stelara losses, Medicare shifts, talc suits and China pressure, banking on new products and expects segment growth to stay on track.",
    "url": "https://finnhub.io/api/news?id=3b1655aa6d8d770d9672a31f0211f6ca98f77527dca12eb33f226d8b07850a32",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765210200,
      "headline": "Can J&J Offset Stelara LOE, MedTech China and Legal Headwinds in 2026?",
      "id": 137737733,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "J&J faces Stelara losses, Medicare shifts, talc suits and China pressure, banking on new products and expects segment growth to stay on track.",
      "url": "https://finnhub.io/api/news?id=3b1655aa6d8d770d9672a31f0211f6ca98f77527dca12eb33f226d8b07850a32"
    }
  },
  {
    "ts": null,
    "headline": "Warren Buffett wouldn’t worry about cash if he retired with just $1M. Here’s why and how to copy his strategy",
    "summary": "Here's how you could copy the Oracle of Omaha in today's market.",
    "url": "https://finnhub.io/api/news?id=56a318e8c7be7e6db779857610d8ac5466b06d3fd14df5185b316aa19b5c4df5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765209660,
      "headline": "Warren Buffett wouldn’t worry about cash if he retired with just $1M. Here’s why and how to copy his strategy",
      "id": 137737730,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Here's how you could copy the Oracle of Omaha in today's market.",
      "url": "https://finnhub.io/api/news?id=56a318e8c7be7e6db779857610d8ac5466b06d3fd14df5185b316aa19b5c4df5"
    }
  },
  {
    "ts": null,
    "headline": "Top-Ranked ETFs to Power Your Portfolio Higher",
    "summary": "With market tailwinds building and optimism returning, these top-ranked ETFs can help investors capture momentum safely.",
    "url": "https://finnhub.io/api/news?id=09c653a2074e50b91ca5b1a50357c2a1f772e3bb6bf997344c8c5d344dbcbec6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765209180,
      "headline": "Top-Ranked ETFs to Power Your Portfolio Higher",
      "id": 137737705,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "With market tailwinds building and optimism returning, these top-ranked ETFs can help investors capture momentum safely.",
      "url": "https://finnhub.io/api/news?id=09c653a2074e50b91ca5b1a50357c2a1f772e3bb6bf997344c8c5d344dbcbec6"
    }
  },
  {
    "ts": null,
    "headline": "Berkshire Hathaway stock picker Todd Combs departs to lead new strategic investment group at JPMorgan",
    "summary": "Berkshire Hathaway's big shake-up across its corporate structure will see its top stock picker depart for JPMorgan.",
    "url": "https://finnhub.io/api/news?id=913834bd958be6c4e8474bc96584d54b3d668d6058728cfcad9f245d5bc74c8f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765208415,
      "headline": "Berkshire Hathaway stock picker Todd Combs departs to lead new strategic investment group at JPMorgan",
      "id": 137732024,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Berkshire Hathaway's big shake-up across its corporate structure will see its top stock picker depart for JPMorgan.",
      "url": "https://finnhub.io/api/news?id=913834bd958be6c4e8474bc96584d54b3d668d6058728cfcad9f245d5bc74c8f"
    }
  },
  {
    "ts": null,
    "headline": "If You Bought 10 Shares of Johnson & Johnson 10 Years Ago, You’d Have This Much Today",
    "summary": "If you bought 10 shares of Johnson & Johnson (JNJ) stock 10 years ago, this is how much it would be worth today.",
    "url": "https://finnhub.io/api/news?id=37c4f8d8ffd96a9c8aba61dae44789145647f6387c55d48b2e3954b8e0a28c74",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765206424,
      "headline": "If You Bought 10 Shares of Johnson & Johnson 10 Years Ago, You’d Have This Much Today",
      "id": 137732214,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "If you bought 10 shares of Johnson & Johnson (JNJ) stock 10 years ago, this is how much it would be worth today.",
      "url": "https://finnhub.io/api/news?id=37c4f8d8ffd96a9c8aba61dae44789145647f6387c55d48b2e3954b8e0a28c74"
    }
  },
  {
    "ts": null,
    "headline": "2026 Market Outlook: S&P 500 To 7600, Healthcare, Renewable Energy, Industrials Will Lead",
    "summary": "Discover why the S&P 500 could hit $7,600 by 2026, driven by AI, sector rotation, and strong consumer trends. Click for my look into the market's future.",
    "url": "https://finnhub.io/api/news?id=9cc1b002a6efaf1fddb5bd4fe481b718786c0396d00abeff24f5abc6760c3a0e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765205708,
      "headline": "2026 Market Outlook: S&P 500 To 7600, Healthcare, Renewable Energy, Industrials Will Lead",
      "id": 137734426,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1334805030/image_1334805030.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Discover why the S&P 500 could hit $7,600 by 2026, driven by AI, sector rotation, and strong consumer trends. Click for my look into the market's future.",
      "url": "https://finnhub.io/api/news?id=9cc1b002a6efaf1fddb5bd4fe481b718786c0396d00abeff24f5abc6760c3a0e"
    }
  },
  {
    "ts": null,
    "headline": "From Condi Rice to Jeff Bezos: The Heavy Hitters on JPMorgan's New Security Council",
    "summary": "JPMorgan Chase named tech billionaires Jeff Bezos and Michael Dell, plus an all-star cast of retired generals and politicians, to advise on its “Security and Resiliency Initiative.” The initiative aims to provide $1.",
    "url": "https://finnhub.io/api/news?id=4c9f1988392915a42c0c66955a44c7deef1bb42fc0a0e816bcb34617195b3022",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765199010,
      "headline": "From Condi Rice to Jeff Bezos: The Heavy Hitters on JPMorgan's New Security Council",
      "id": 137732215,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JPMorgan Chase named tech billionaires Jeff Bezos and Michael Dell, plus an all-star cast of retired generals and politicians, to advise on its “Security and Resiliency Initiative.” The initiative aims to provide $1.",
      "url": "https://finnhub.io/api/news?id=4c9f1988392915a42c0c66955a44c7deef1bb42fc0a0e816bcb34617195b3022"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Breakfast Podcast: IBM Eyes Another AI Deal",
    "summary": "IBM will reportedly pay $11B for the data streaming company. Lilly, Pfizer, J&J in Chinaâs private insurance catalog. White House rolling out $12B in aid for farmers.",
    "url": "https://finnhub.io/api/news?id=3a3c499cd69efc9da8e1fd02397acddcaf504b138226db1ea77b156f9511ca81",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765178152,
      "headline": "Wall Street Breakfast Podcast: IBM Eyes Another AI Deal",
      "id": 137730932,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2181778905/image_2181778905.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "IBM will reportedly pay $11B for the data streaming company. Lilly, Pfizer, J&J in Chinaâs private insurance catalog. White House rolling out $12B in aid for farmers.",
      "url": "https://finnhub.io/api/news?id=3a3c499cd69efc9da8e1fd02397acddcaf504b138226db1ea77b156f9511ca81"
    }
  },
  {
    "ts": null,
    "headline": "MGV: Why I Like Vanguard's Mega-Cap Value ETF Here",
    "summary": "MGV trades at a 28% P/E and 42% price-to-book discount to the S&P 500, offering attractive relative value and sector diversification. Read why MGV ETF is a Buy.",
    "url": "https://finnhub.io/api/news?id=7e21aa18e6d8d971297524d990bed7bcd45e9685ca55c47f3b9f730952d4807c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765157171,
      "headline": "MGV: Why I Like Vanguard's Mega-Cap Value ETF Here",
      "id": 137729545,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/880121294/image_880121294.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "MGV trades at a 28% P/E and 42% price-to-book discount to the S&P 500, offering attractive relative value and sector diversification. Read why MGV ETF is a Buy.",
      "url": "https://finnhub.io/api/news?id=7e21aa18e6d8d971297524d990bed7bcd45e9685ca55c47f3b9f730952d4807c"
    }
  },
  {
    "ts": null,
    "headline": "RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study",
    "summary": "Johnson & Johnson today announced final overall survival (OS) results from the Asia patients of the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib monotherapy showed amivantamab plus lazertinib led to a clinically meaningful OS improvement in the first-line treatment of Asian patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations. Median OS fo",
    "url": "https://finnhub.io/api/news?id=2cf3779a9c96393d6f5e0f99b0045b15f88cf0827903c8ac0947435e50839039",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765155600,
      "headline": "RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study",
      "id": 137732216,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson today announced final overall survival (OS) results from the Asia patients of the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib monotherapy showed amivantamab plus lazertinib led to a clinically meaningful OS improvement in the first-line treatment of Asian patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations. Median OS fo",
      "url": "https://finnhub.io/api/news?id=2cf3779a9c96393d6f5e0f99b0045b15f88cf0827903c8ac0947435e50839039"
    }
  }
]